[go: up one dir, main page]

Markiewicz et al., 1986 - Google Patents

Evaluation of the hereditary Syrian hamster cardiomyopathy by 31P nuclear magnetic resonance spectroscopy: improvement after acute verapamil therapy.

Markiewicz et al., 1986

View PDF
Document ID
8147009168610800343
Author
Markiewicz W
Wu S
Parmley W
Higgins C
Sievers R
James T
Wikman-Coffelt J
Jasmin G
Publication year
Publication venue
Circulation research

External Links

Snippet

The relation between metabolic and functional derangement in various cardiomyopathies has not been well characterized. This information was specifically sought in a spontaneous cardiomyopathic model. Metabolic and hemodynamic parameters were obtained in glucose …
Continue reading at www.ahajournals.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P-C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Markiewicz et al. Evaluation of the hereditary Syrian hamster cardiomyopathy by 31P nuclear magnetic resonance spectroscopy: improvement after acute verapamil therapy.
VAAGENES et al. Amelioration of brain damage by lidoflazine after prolonged ventricular fibrillation cardiac arrest in dogs
Bünger et al. Pyruvate‐enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart: Near‐complete prevention of reperfusion contractile failure
Neubauer et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure.
Murphy et al. Amiloride delays the ischemia-induced rise in cytosolic free calcium.
Gesek et al. Insulin increases Na (+)-H+ exchange activity in proximal tubules from normotensive and hypertensive rats
Borchgrevink et al. Magnesium and reperfusion of ischemic rat heart as assessed by 31P-NMR
Salhany et al. 31P nuclear magnetic resonance measurement of cardiac pH in perfused guinea-pig hearts
Allard et al. Preischemic glycogen reduction or glycolytic inhibition improves postischemic recovery of hypertrophied rat hearts
Maruki et al. Intracellular pH during reperfusion influences evoked potential recovery after complete cerebral ischemia.
Lehr Magnesium and cardiac necrosis
Barnes et al. Skeletal muscle metabolism in myotonic dystrophy A 31P magnetic resonance spectroscopy study.
Nioka et al. Substrate regulation of mitochondrial oxidative phosphorylation in hypercapnic rabbit muscle
Ratcliffe et al. Acute renal failure in hemorrhagic hypotension: cellular energetics and renal function
Neubauer et al. Verapamil attenuates ATP depletion during hypoxia: 31P NMR studies of the isolated rat heart
Griffin et al. Role of endothelium-derived nitric oxide in hemodynamic adaptations after graded renal mass reduction
Xia et al. Effects of ischemia on intracellular sodium and phosphates in the in vivo rat liver
Mizelle et al. Role of renal nerves in compensatory adaptation to chronic reductions in sodium intake
Lavanchy et al. Effects of diltiazem on the energy metabolism of the isolated rat heart submitted to ischaemia: a 31P NMR study
Meyer et al. Effect of decreased pH on force and phosphocreatine in mammalian skeletal muscle
Sumpio et al. Adenosine Triphosphate—Magnesium Chloride Ameliorates Reperfusion Injury Following Ischemia as Determined by Phosphorus Nuclear Magnetic Resonance
Heath et al. Concentration of brain free magnesium following severe brain injury correlates with neurologic motor outcome
Rady et al. Characterization of systemic oxygen transport in end-stage chronic congestive heart failure
Miyoshi et al. Effects of magnesium and its mechanism on the incidence of reperfusion arrhythmias following severe ischemia in isolated rat hearts
Chuck et al. Direct pharmacologic and osmolal effects of contrast media on the mechanics of heart muscle isolated from cats